Filter Results:
(1,252)
Show Results For
- All HBS Web
(1,252)
- People (5)
- News (169)
- Research (918)
- Events (6)
- Multimedia (12)
- Faculty Publications (752)
Show Results For
- All HBS Web
(1,252)
- People (5)
- News (169)
- Research (918)
- Events (6)
- Multimedia (12)
- Faculty Publications (752)
- December 1991
- Teaching Note
Eli Lilly and Co.: European Pharmaceutical Operations, Teaching Note
By: Francis Aguilar
- 2008
- Chapter
Where is the Pharmacy to the World? Pharmaceutical Industry Location and International Regulatory Variation
By: Arthur A. Daemmrich
A consumer-oriented model for drug development and use has attracted attention in recent years as an alternative to the much-maligned approach of mass-marketing blockbuster drugs. In a parallel development, patients and disease-based organizations have assumed greater... View Details
Keywords: Geographic Location; Governing Rules, Regulations, and Reforms; Health Testing and Trials; Demand and Consumers; Pharmaceutical Industry; European Union; Germany; United States
Daemmrich, Arthur A. "Where is the Pharmacy to the World? Pharmaceutical Industry Location and International Regulatory Variation." Chap. 16 in Ways of Regulating: Therapeutic Agents between Plants, Shops, and Consulting Rooms. Vol. 363, edited by Jean Paul Gaudillière and Volker Hess, 271–290. Berlin, Germany: Max-Planck-Institut für Wissenschaftsgeschichte, 2008.
- 2007
- Article
Pharmacovigilance and the Missing Denominator: The Changing Context of Pharmaceutical Risk Mitigation
By: Arthur A. Daemmrich
In the wake of Vioxx, Avandia, and other recent prominent cases of drugs found to cause side effects after marketing, the safety of pharmaceuticals has come to the forefront of American public policy. Press attention, congressional investigations, and legislative... View Details
Keywords: Brands and Branding; Policy; Risk Management; Government Legislation; Risk and Uncertainty; Goals and Objectives; Customers; Pharmaceutical Industry; Pharmaceutical Industry; United States
Daemmrich, Arthur A. "Pharmacovigilance and the Missing Denominator: The Changing Context of Pharmaceutical Risk Mitigation." Pharmacy in History 49, no. 2 (2007): 61–75.
- 01 Jun 2020
- Working Paper Summaries
Rebates in the Pharmaceutical Industry: Evidence from Medicines Sold in Retail Pharmacies in the U.S.
- February 1990
- Background Note
Note on Pharmaceutical Marketing Practices in the Third World (Edited)
Smith, N. Craig, and John A. Quelch. "Note on Pharmaceutical Marketing Practices in the Third World (Edited)." Harvard Business School Background Note 590-032, February 1990.
- 8 Mar 2012
- Other Presentation
Competing by Saving Lives: How Pharmaceutical and Medical Device Companies Create Shared Value in Global Health
How Pharmaceutical and Medical Device Companies Create Shared Value in Global Health View Details
Porter, Michael E. "Competing by Saving Lives: How Pharmaceutical and Medical Device Companies Create Shared Value in Global Health." Creating Shared Value in Global Health, FSG, New York City, NY, United States , March 8, 2012.
- 22 Apr 2009
- Working Paper Summaries
Where is the Pharmacy to the World? International Regulatory Variation and Pharmaceutical Industry Location
- 2012
- Report
Competing by Saving Lives: How Pharmaceutical and Medical Device Companies Create Shared Value in Global Health
By: Mark R. Kramer, Kyle Peterson, Matthew Rehrig, Mike Stamp and Samuel Kim
Examples of how pharmaceutical and medical companies are addressing unmet health needs in low- and middle- income economies, creating shared value by providing products and services that tackle global health problems. View Details
Keywords: Shared Value; Low- And Middle-income Economies; Health Care and Treatment; Global Range; Pharmaceutical Industry; Pharmaceutical Industry
Kramer, Mark R., Kyle Peterson, Matthew Rehrig, Mike Stamp, and Samuel Kim. "Competing by Saving Lives: How Pharmaceutical and Medical Device Companies Create Shared Value in Global Health." Report, FSG, 2012.
- September 2017
- Teaching Note
Dr. William Carson— Intrapreneurial Innovation in the Pharmaceutical Industry
By: Steven Rogers and Alyssa Haywoode
Teaching Note for HBS No. 318-005. View Details
- June 1989 (Revised July 1990)
- Background Note
Note on Pharmaceutical Marketing Practices in the Third World
Smith, N. Craig, and John A. Quelch. "Note on Pharmaceutical Marketing Practices in the Third World." Harvard Business School Background Note 589-039, June 1989. (Revised July 1990.)
- August 1994 (Revised March 1995)
- Supplement
Kurt Landgraf and Du Pont Merck Pharmaceutical Company (B)
Supplements the (A) case. View Details
Gentile, Mary C., and Sarah Gant. "Kurt Landgraf and Du Pont Merck Pharmaceutical Company (B)." Harvard Business School Supplement 395-035, August 1994. (Revised March 1995.)
- 06 Sep 2022
- News
Our September Issue: Nurses, Care Delivery, Pharmaceuticals & More
- 05 Jul 2006
- Working Paper Summaries
Do Managers’ Heuristics Affect R&D Performance Volatility? A Simulation Informed by the Pharmaceutical Industry
- Article
Knowledge Spillovers, Geographic Location, and the Productivity of Pharmaceutical Research
By: Jeffrey Furman, Margaret K. Kyle, Iain Cockburn and Rebecca M. Henderson
Furman, Jeffrey, Margaret K. Kyle, Iain Cockburn, and Rebecca M. Henderson. "Knowledge Spillovers, Geographic Location, and the Productivity of Pharmaceutical Research." Annales d'économie et de statistique, nos. 79-80 (July–December 2005).
- 2001
- Working Paper
Asset Accumulation, Interdependence and Technological Change: Evidence from Pharmaceutical Drug Discovery
By: Stefan Thomke and Walter Kuemmerle
- July 2002
- Article
Asset Accumulation, Interdependence and Technological Change: Evidence from Pharmaceutical Drug Discovery
By: Stefan Thomke and Walter Kuemmerle
Thomke, Stefan, and Walter Kuemmerle. "Asset Accumulation, Interdependence and Technological Change: Evidence from Pharmaceutical Drug Discovery." Strategic Management Journal 23, no. 7 (July 2002): 619–635.
- May 2024
- Article
Tepid Uptake of Digital Health Technologies in Clinical Trials by Pharmaceutical and Medical Device Firms
By: Caroline Marra and Ariel D. Stern
Digital health technologies (DHTs) can enable more patient-centric therapeutic development by generating evidence that captures how patients feel and function, enabling decentralized trial designs that increase participant inclusivity and convenience, and collecting... View Details
Keywords: Health Care and Treatment; Technological Innovation; Product Development; Health Testing and Trials; Governing Rules, Regulations, and Reforms
Marra, Caroline, and Ariel D. Stern. "Tepid Uptake of Digital Health Technologies in Clinical Trials by Pharmaceutical and Medical Device Firms." Clinical Pharmacology & Therapeutics 115, no. 5 (May 2024): 988–992.